TP53 and neoplasm: Furthermore, the combination of JQ1 and a MEK inhibitor PD-901 was found to cause significant tumor regression in a genetically engineered mouse model with cis mutations of Nf1, p53, and Suz12 compared to JQ1 or PD-901 alone.